Prostamax
Hormonal / ProstateAlso known as: Lys-Glu-Asp-Pro, KEDP, Prostate Bioregulator
Mechanism
Prostamax is a tetrapeptide bioregulator designed to support prostate health. It is part of Professor Khavinson's organ-specific peptide series, where short peptides are matched to specific tissues. Prostamax targets prostate tissue, where it helps normalize gland function by reducing inflammation, supporting healthy cell differentiation, and potentially reactivating genes that become silenced during aging. It has been studied primarily in animal models of prostatitis and benign prostatic hyperplasia (BPH).
Technical detail
Synthetic tetrapeptide (Lys-Glu-Asp-Pro) designed as a prostate-specific bioregulator per Khavinson's peptide bioregulation theory. Proposed mechanism: interaction with chromatin in prostate epithelial and stromal cells, promoting chromatin decondensation and deheterochromatinization — reactivating genes repressed during cellular aging. Increases frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs) while reducing pericentromeric heterochromatin segments. Preclinical data suggests normalization of androgen receptor expression, reduction of inflammatory cytokine gene transcription (IL-8, TNF-alpha) in prostate stromal cells, and restoration of differentiated secretory cell function. In rat models, reduced prostate swelling, vascular congestion, immune cell infiltration, and scarring.
Effects
REPRODUCTIVE/PROSTATE: Primary target tissue. Designed as a prostate-specific bioregulator. Proposed mechanism: interacts with chromatin in prostate epithelial and stromal cells, promoting chromatin decondensation and deheterochromatinization — reactivating genes repressed during cellular aging. In animal models of prostatitis: reduced prostate swelling, vascular congestion (hyperemia), decreased immune cell infiltration, and reduced fibrotic scarring. Normalization of androgen receptor expression in prostate tissue (animal data). Reduction of inflammatory cytokine gene transcription (IL-8, TNF-alpha) in prostate stromal cells. Restoration of differentiated secretory cell function. In cell culture studies: increased frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin — these are markers of gene activation. IMMUNE: Anti-inflammatory effects in prostate tissue — reduced immune cell infiltration suggests modulation of local inflammatory response. ENDOCRINE: May normalize local hormonal milieu in prostate tissue — androgen receptor normalization could improve DHT sensitivity/responsiveness. CARDIOVASCULAR: No direct cardiovascular effects documented. Reduced prostatic vascular congestion is a local, not systemic, effect. UROLOGICAL: Improved urinary function secondary to reduced prostate inflammation and swelling (animal, practitioner reports). BPH symptoms (frequency, urgency, incomplete emptying) may improve. METABOLIC: No direct metabolic effects documented. Tier 3: Used by anti-aging practitioners for prostate health maintenance, particularly in men over 50. Practitioners report improvement in urinary symptoms within 4-8 weeks. Often combined with Vesilute for comprehensive urogenital support.
Practitioner Guide
DOSING TIPS: Standard Khavinson bioregulator protocol: 10-20mg subcutaneous injection daily for 10-30 days, repeated 2-3 times per year. Also available as oral capsules (enteric-coated) — 1-2 capsules daily for 30 days. Some practitioners alternate injectable and oral courses. Start with oral for patient convenience; switch to injectable if response is suboptimal. RECONSTITUTION: For injectable use — reconstitute lyophilized powder with bacteriostatic water. Typical concentration: 10mg/mL or 20mg/mL. INJECTION SITE: Subcutaneous — abdominal fat pad or thigh. Lower abdominal injection (closer to target tissue) is sometimes preferred by practitioners, though no evidence supports site-specific targeting via SubQ injection for peptides. TIMING: No specific timing requirements. Some practitioners prefer morning administration. Take oral form with meals. SUPPLEMENT SYNERGIES: Stack with Vesilute for urogenital support (Prostamax for prostate + Vesilute for smooth muscle/vascular). Saw palmetto (5-alpha reductase inhibitor) complements from a different mechanism. Zinc is essential for prostate health — 30-50mg/day. Lycopene (antioxidant with prostate tropism). Stinging nettle root for urinary symptom support. CYCLING: Course-based protocol — 10-30 days on, then 3-6 month break. 2-3 courses per year. This follows the Khavinson bioregulator paradigm. STACKING: Prostate health stack: Prostamax + Vesilute + Zinc + Saw Palmetto. Anti-aging triad for men: Prostamax + Epithalon + Thymalin. Urogenital: Prostamax + Vesilute + KPV (anti-inflammatory). CONTRAINDICATION NUANCES: Prostate cancer — use with caution. While bioregulators theoretically promote normal cell function (not cancer growth), no data exists on effects in malignant prostate tissue. Screen PSA before starting. Active prostate infection — treat infection first. STORAGE: Lyophilized — room temperature or refrigerated. Capsules — room temperature. PATIENT EDUCATION: This is a bioregulator — it does not directly shrink the prostate or block hormones like finasteride. Instead, it helps prostate cells maintain healthy gene expression as they age. Effects are gradual (2-4 weeks onset) and cumulative over multiple courses. Track PSA, urinary symptom scores (IPSS), and subjective improvement. Best suited for preventive maintenance in men over 40-50, not acute treatment of severe BPH or cancer.
Research Summary
TIER 1 (Gold Standard): No Western RCTs exist for Prostamax specifically. TIER 2 (Strong): Khavinson VK et al. — multiple publications on peptide bioregulators and organ-specific effects (Advances in Gerontology, Bulletin of Experimental Biology and Medicine). Peptide-DNA interaction studies demonstrating short peptides modulating gene expression at promoter regions (Khavinson et al., 2012). General chromatin remodeling by Khavinson peptides is published in peer-reviewed Russian journals. TIER 3 (Moderate): Russian clinical data on prostate bioregulator use — published in Russian medical literature but not indexed in PubMed. Animal studies on prostatitis models showing reduced inflammation and tissue damage. Practitioner case series from European and Russian anti-aging clinics. Post-marketing surveillance data from Russia (10+ years). Community reports of urinary symptom improvement. KEY FINDINGS: (1) The prostate-specific bioregulator concept is plausible given organ-specific gene expression patterns. (2) Animal data supports anti-inflammatory and tissue-normalizing effects. (3) Limited Western validation. (4) Safety profile appears excellent based on clinical use history. GAPS: No Western clinical trials. Mechanism at molecular level not fully elucidated. Optimal patient selection criteria. Comparison with standard BPH treatments. ACTIVE TRIALS: None registered on ClinicalTrials.gov.